Rituximab
Biopharmaceutical drug
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
15
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy]
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Lists
0
.svg/500px-Pfizer_(2021).svg.png)